Donate

Takeda Suspends Screening & Further Enrollment in TAK-754, TAK-748 Clinical Studies

August 21, 2020

The following is an excerpt from an update from Takeda. Read the update in its entirety here. Takeda recently informed HFA of it’s decision聽to suspend screening and further enrollment in聽the TAK-754 and TAK-748 clinical studies, effective immediately. TAK-754 is an AAV8 gene therapy for the treatment of hemophilia A currently in Phase 1/2 clinical聽development, while […]


Sign up for E-mails, Dateline Magazine, and other ways to stay connected.